What do you think about your investment in IHH? Was it the right decision?
IHH is an attractive vehicle for us because it has a strong track record across multiple countries in Asia of providing premium healthcare services, applying the latest healthcare technologies and employing the best healthcare professionals. We believe that by growing IHH we can deliver a significant quantitative and qualitative improvement in the provision of medical services in Asia and help to address the pressing supply-demand gap.
How confident are you regarding your investment in Fortis, since you are the largest shareholder?
Given the track record of IHH’s growth across other regions, we have confidence that IHH will continue to execute the turnaround plan for Fortis Healthcare and we hope to see the positive results continue.
What are your plans in healthcare in India?
Our other current investments in the Indian healthcare and pharma market include Keimed (pharma distributor) and GOQii (health platform). We view the Indian healthcare market as highly attractive, particularly the private hospital sector, which accounts for 80% of the total healthcare market in India… we will rather focus on IHH than look for more investments, although we continue to be keen to explore further, given the huge and growing market opportunity in the Indian healthcare segment overall.
Do you think you should go slow with other plans of investment related to Fortis, given that the court is yet to take a decision?
We firmly believe in IHH’s global expertise in turning around firms to profitability, as has been shown in its turnaround of Fortis Healthcare. We also remain committed to and are confident on the potential of the Indian market.